Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETON NASDAQ:JMAC NASDAQ:MNPR NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$18.64+0.5%$18.45$7.58▼$23.00$500.56M1.16351,259 shs54,139 shsJMACMaxpro Capital Acquisition$36.65+14.6%$12.89$7.50▼$19.22$492.14M0.0174,040 shs142,968 shsMNPRMonopar Therapeutics$76.43-1.6%$60.93$4.50▼$105.00$471.62M1.4245,604 shs53,632 shsSPROSpero Therapeutics$2.29-3.6%$2.04$0.51▼$3.22$128.03M1.471.65 million shs652,487 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals+0.82%-1.17%+1.15%+21.32%+119.79%JMACMaxpro Capital Acquisition0.00%+98.83%+98.83%+463.85%+26,690.94%MNPRMonopar Therapeutics+0.65%-18.51%+22.69%+65.67%+1,379.05%SPROSpero Therapeutics+3.49%+0.42%+18.50%-0.42%+85.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$18.64+0.5%$18.45$7.58▼$23.00$500.56M1.16351,259 shs54,139 shsJMACMaxpro Capital Acquisition$36.65+14.6%$12.89$7.50▼$19.22$492.14M0.0174,040 shs142,968 shsMNPRMonopar Therapeutics$76.43-1.6%$60.93$4.50▼$105.00$471.62M1.4245,604 shs53,632 shsSPROSpero Therapeutics$2.29-3.6%$2.04$0.51▼$3.22$128.03M1.471.65 million shs652,487 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals+0.82%-1.17%+1.15%+21.32%+119.79%JMACMaxpro Capital Acquisition0.00%+98.83%+98.83%+463.85%+26,690.94%MNPRMonopar Therapeutics+0.65%-18.51%+22.69%+65.67%+1,379.05%SPROSpero Therapeutics+3.49%+0.42%+18.50%-0.42%+85.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals 2.40Hold$29.6759.20% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/AMNPRMonopar Therapeutics 3.00Buy$105.6738.26% UpsideSPROSpero Therapeutics 2.17Hold$5.00118.82% UpsideCurrent Analyst Ratings BreakdownLatest SPRO, MNPR, JMAC, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025MNPRMonopar TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$125.0010/13/2025MNPRMonopar TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$125.0010/13/2025SPROSpero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MNPRMonopar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SPROSpero TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025ETONEton PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/6/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$80.00 ➝ $142.0010/6/2025SPROSpero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/2/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$77.00 ➝ $115.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$58.18M8.59N/AN/A$0.94 per share19.82JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ASPROSpero Therapeutics$34.09M3.77N/AN/A$0.85 per share2.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$3.82M-$0.16N/A37.27N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)JMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AMNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$0.98N/AN/AN/A-110.35%-120.27%-55.61%11/13/2025 (Estimated)Latest SPRO, MNPR, JMAC, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025MNPRMonopar Therapeutics-$0.48N/AN/AN/AN/AN/A11/13/2025Q3 2025SPROSpero Therapeutics-$0.25N/AN/AN/AN/AN/A11/11/2025Q3 2025ETONEton Pharmaceuticals$0.13N/AN/AN/A$20.47 millionN/A8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/12/2025Q2 2025SPROSpero Therapeutics-$0.38-$0.03+$0.35-$0.03$11.00 million$14.19 million8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.062.63%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton Pharmaceuticals1.141.771.16JMACMaxpro Capital AcquisitionN/AN/AN/AMNPRMonopar TherapeuticsN/A33.9333.93SPROSpero TherapeuticsN/A3.973.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%JMACMaxpro Capital Acquisition73.18%MNPRMonopar Therapeutics1.83%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals14.89%JMACMaxpro Capital Acquisition19.27%MNPRMonopar Therapeutics20.50%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals2026.82 million22.83 millionOptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableSPROSpero Therapeutics15056.28 million53.18 millionOptionableSPRO, MNPR, JMAC, and ETON HeadlinesRecent News About These CompaniesSpero Therapeutics stock surges after positive Phase 3 UTI drug dataOctober 21 at 11:00 AM | za.investing.comPIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)October 21 at 5:58 AM | uk.finance.yahoo.comPIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)October 21 at 2:00 AM | globenewswire.comZacks Research Downgrades Spero Therapeutics (NASDAQ:SPRO) to HoldOctober 15, 2025 | marketbeat.comSpero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeekOctober 14, 2025 | globenewswire.comBest Momentum Stock to Buy for October 10thOctober 10, 2025 | zacks.comSpero Therapeutics' (SPRO) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Rating Increased to Strong-Buy at Zacks ResearchOctober 8, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Receives Consensus Rating of "Hold" from BrokeragesOctober 3, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Director Sells $12,946.84 in StockSeptember 4, 2025 | insidertrades.comDown 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a TurnaroundAugust 19, 2025 | zacks.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 13, 2025 | finanznachrichten.deSpero Therapeutics Reports Q2 2025 Results and Trial SuccessAugust 13, 2025 | msn.comSpero Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comSpero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comSpero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comSpero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025August 5, 2025 | globenewswire.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28, 2025 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Sprouts, Darden Offer High-Upside Setups for Risk-TakersBy Sam Quirke | September 26, 2025ISRG, TEAM, SFM Trade Well Below Highs With 30%+ UpsideBy Leo Miller | September 23, 20253 Reasons to Buy Sprouts Farmers Market Ahead of EarningsBy Sam Quirke | October 12, 2025SPRO, MNPR, JMAC, and ETON Company DescriptionsEton Pharmaceuticals NASDAQ:ETON$18.64 +0.09 (+0.46%) As of 12:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Maxpro Capital Acquisition NASDAQ:JMAC$36.65 +4.67 (+14.60%) As of 10/17/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Monopar Therapeutics NASDAQ:MNPR$76.09 -1.56 (-2.01%) As of 12:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Spero Therapeutics NASDAQ:SPRO$2.28 -0.09 (-3.59%) As of 12:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
